Found: 133
Select item for more details and to access through your institution.
Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK.
- Published in:
- ESC Heart Failure, 2019, v. 6, n. 2, p. 280, doi. 10.1002/ehf2.12402
- By:
- Publication type:
- Article
Estimating the value of sodium‐glucose cotransporter‐2 inhibitors within the context of contemporary guidelines and the totality of evidence.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1830, doi. 10.1111/dom.15040
- By:
- Publication type:
- Article
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 639, doi. 10.1111/dom.14917
- By:
- Publication type:
- Article
Eight‐year trends in obesity‐related complications and health care cost progression in a US population with obesity: A retrospective cohort study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 536, doi. 10.1111/dom.14897
- By:
- Publication type:
- Article
Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long‐term cost‐effectiveness analysis based on SUSTAIN 11.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 491, doi. 10.1111/dom.14892
- By:
- Publication type:
- Article
Healthcare costs and hospitalizations in US patients with type 2 diabetes and cardiovascular disease: A retrospective database study (OFFSET).
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 7, p. 1300, doi. 10.1111/dom.14703
- By:
- Publication type:
- Article
Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 3, p. 377, doi. 10.1111/dom.14603
- By:
- Publication type:
- Article
A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2227, doi. 10.1111/dom.14196
- By:
- Publication type:
- Article
Cost‐effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1047, doi. 10.1111/dom.13992
- By:
- Publication type:
- Article
Systematic literature review and network meta‐analysis of sodium‐glucose co‐transporter inhibitors vs metformin as add‐on to insulin in type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 1, p. 39, doi. 10.1111/dom.13863
- By:
- Publication type:
- Article
Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 3, p. 467, doi. 10.1111/dom.13550
- By:
- Publication type:
- Article
An alternative approach to modelling HbA1c trajectories in patients with type 2 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 5, p. 628, doi. 10.1111/dom.12865
- By:
- Publication type:
- Article
Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 5, p. 644, doi. 10.1111/dom.12867
- By:
- Publication type:
- Article
Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate.
- Published in:
- Diabetes, Obesity & Metabolism, 2004, v. 6, n. 4, p. 299, doi. 10.1111/j.1462-8902.2004.00340.x
- By:
- Publication type:
- Article
The Authors’ Reply.
- Published in:
- 2006
- By:
- Publication type:
- Letter
A Model of Long-term Metabolic Progression of Type 2 Diabetes Mellitus for Evaluating Treatment Strategies.
- Published in:
- PharmacoEconomics, 2006, p. 5, doi. 10.2165/00019053-200624001-00002
- By:
- Publication type:
- Article
A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies.
- Published in:
- 2006
- By:
- Publication type:
- journal article
α<sub>1</sub>-Proteinase Inhibitor (Human) in the Treatment of Hereditary Emphysema Secondary to α<sub>1</sub>-Antitrypsin Deficiency.
- Published in:
- Clinical Drug Investigation, 2012, v. 32, n. 5, p. 354, doi. 10.2165/11631920-000000000-00000
- By:
- Publication type:
- Article
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review.
- Published in:
- Diabetes Therapy, 2024, v. 15, n. 5, p. 1099, doi. 10.1007/s13300-024-01550-5
- By:
- Publication type:
- Article
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK.
- Published in:
- Diabetes Therapy, 2023, v. 14, n. 6, p. 1005, doi. 10.1007/s13300-023-01408-2
- By:
- Publication type:
- Article
An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2023, v. 14, n. 1, p. 123, doi. 10.1007/s13300-022-01344-7
- By:
- Publication type:
- Article
Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 5, p. 889, doi. 10.1007/s13300-022-01242-y
- By:
- Publication type:
- Article
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 5, p. 847, doi. 10.1007/s13300-022-01228-w
- By:
- Publication type:
- Article
Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 2, p. 241, doi. 10.1007/s13300-022-01204-4
- By:
- Publication type:
- Article
Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 2, p. 225, doi. 10.1007/s13300-021-01201-z
- By:
- Publication type:
- Article
The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 11, p. 2817, doi. 10.1007/s13300-021-01162-3
- By:
- Publication type:
- Article
One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 6, p. 1593, doi. 10.1007/s13300-021-01061-7
- By:
- Publication type:
- Article
Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Risk Prediction of the Diabetes Missing Million: Identifying Individuals at High Risk of Diabetes and Related Complications.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 1, p. 87, doi. 10.1007/s13300-020-00963-2
- By:
- Publication type:
- Article
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 1, p. 55, doi. 10.1007/s13300-020-00951-6
- By:
- Publication type:
- Article
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 12, p. 2757, doi. 10.1007/s13300-020-00930-x
- By:
- Publication type:
- Article
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 10, p. 2221, doi. 10.1007/s13300-020-00917-8
- By:
- Publication type:
- Article
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 10, p. 2207, doi. 10.1007/s13300-020-00911-0
- By:
- Publication type:
- Article
Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 9, p. 1925, doi. 10.1007/s13300-020-00889-9
- By:
- Publication type:
- Article
Diabetes and Novel Coronavirus Infection: Implications for Treatment.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 9, p. 1915, doi. 10.1007/s13300-020-00858-2
- By:
- Publication type:
- Article
What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 6, p. 1381, doi. 10.1007/s13300-020-00834-w
- By:
- Publication type:
- Article
Drug Therapy in Obesity: A Review of Current and Emerging Treatments.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 6, p. 1199, doi. 10.1007/s13300-020-00816-y
- By:
- Publication type:
- Article
Correction to: Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 2, p. 369, doi. 10.1007/s13300-019-00747-3
- By:
- Publication type:
- Article
Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 1, p. 37, doi. 10.1007/s13300-019-00728-6
- By:
- Publication type:
- Article
Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 5, p. 1793, doi. 10.1007/s13300-019-00685-0
- By:
- Publication type:
- Article
What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 5, p. 1719, doi. 10.1007/s13300-019-00678-z
- By:
- Publication type:
- Article
Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice.
- Published in:
- 2019
- By:
- Publication type:
- Correction Notice
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 5, p. 1595, doi. 10.1007/s13300-019-0657-8
- By:
- Publication type:
- Article
A Summary of 2018 and What Lies Ahead for Diabetes Therapy in 2019.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 1, p. 1, doi. 10.1007/s13300-018-0559-1
- By:
- Publication type:
- Article
Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 5, p. 1729, doi. 10.1007/s13300-018-0494-1
- By:
- Publication type:
- Article
Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 5, p. 1919, doi. 10.1007/s13300-018-0478-1
- By:
- Publication type:
- Article
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 5, p. 1757, doi. 10.1007/s13300-018-0471-8
- By:
- Publication type:
- Article
Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective.
- Published in:
- Patient Preference & Adherence, 2013, v. 7, p. 925, doi. 10.2147/PPA.S46805
- By:
- Publication type:
- Article
The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program.
- Published in:
- Vaccines, 2022, v. 10, n. 2, p. 140, doi. 10.3390/vaccines10020140
- By:
- Publication type:
- Article